By Fineline Cube 
Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.
Market Potential and Development
Currently, no oral GnRH antagonist has been approved in China. Livzon plans to advance the development and commercialization of this Class 1 chemical new drug across Mainland China, Hong Kong, and Macao.
Mechanism and Advantages
GnRH antagonists function by directly blocking pituitary GnRH receptors, inhibiting the synthesis and release of sex hormones. Key advantages include rapid onset, avoidance of hormonal “flare-up,” short treatment cycles, and quick recovery of pituitary function post-treatment.
Innovation and Patient Compliance
Livzon’s oral GnRH antagonist stands out from existing injectable options, significantly improving patient compliance. Notably, no oral GnRH antagonist products have been launched in China, and globally, none exist for assisted reproduction indications.-Fineline Info & Tech